Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.57 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | PYGL | P06737 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16127850 | 0.91 | PTGER4 (0.67) | KMT2ACYP1A2CYP2C19PTGER4PTGER2 | |
| SCHEMBL16088672 | 0.87 | PTGER4 (0.63) | KMT2ACYP1A2CYP2C19PTGER4PTGER2 | |
| SCHEMBL16127851 | 0.85 | PTGER4 (0.67) | KMT2ACYP1A2CYP2C19PTGER4PTGER2 | |
| SCHEMBL16088676 | 0.82 | AKR1C3 (0.55) | KMT2AALDH1A1APEX1NR1H4EPHX2 | |
| SCHEMBL16088690 | 0.82 | APEX1 (0.79) | KMT2ACYP1A2CYP2C19ALDH1A1APEX1 | |
| SCHEMBL23864209 | 0.82 | PTGER4 (0.51) | KMT2ACYP1A2CYP2C19PTGER4PTGER2 | |
| SCHEMBL29404059 | 0.77 | PTGER4 (0.74) | CYP1A2PTGER4PTGER2ALDH1A1NR1H4 | |
| SCHEMBL16088696 | 0.77 | AKR1C3 (0.55) | KMT2AALDH1A1APEX1NR1H4EPHX2 | |
| SCHEMBL24735197 | 0.77 | PTGER4 (0.74) | CYP1A2PTGER4PTGER2ALDH1A1NR1H4 | |
| SCHEMBL29002468 | 0.77 | NR1H4 (0.76) | KMT2AALDH1A1NR1H4EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452170-B2 | Compounds and methods for inducing chondrogenesis | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160045514-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-02-18 | — | — | US | disclosed |
| US-20140271955-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045514-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | COL2A1, BMP4, COL1A1 | KMT2A 3871/4885CYP1A2 3874/4885CYP2C19 4881/4885 |
| US-20140271955-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | COL2A1, BMP4, COL1A1 | KMT2A 3871/4885CYP1A2 3874/4885CYP2C19 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.